Recent Media
Forward Looking Statements
These media presentations and interviews contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in these media presentations and interviews are forward-looking statements. Forward-looking statements contained in these media presentations and interviews may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s SEC filings. Forward-looking statements contained in the media presentations and interviews are made as of the dates thereof, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of these media presentations and interviews.
2024 Oct – OncLive – Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis
Dr. Giuseppe Del Priore, BriaCell’s CMO, and Dr. William V. Williams, BriaCell’s CEO, are featured to discuss BriaCell reporting of 100% Resolution of brain metastasis in breast cancer patient with “eye-bulging” tumor
=============================================================================================================
2024 Sept – OncLive – BRIA-ABC Trial Explores Novel Post-ADC Strategy for Metastatic Breast Cancer
Principal Investigator, and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, and BriaCell’s Medical Advisory Board Member, and Professor of Medicine at the University of Pittsburgh School of Medicine, Adam M. Brufsky, MD, PhD, discuss the evaluation of Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer
=============================================================================================================
